P

Protalix BioTherapeutics

D
PLX
USD
-0.015
(-1.2931%)
Market Open
3,772.00
Volume
0.08
EPS
-
Div Yield
12.778
P/E
84,009,942.60
Market Cap
Today
-0.8621%
1 Week
-3.361%
1 Month
-7.258%
6 Months
-31.548%
12 Months
-56.357%
Year To Date
-35.393%
All Time
0%
News

Novo Nordisk Surges in Profit and Sales

02.05.2024
Stocks news
More
Related Instruments
A
ALIM
0.19
(5.2925%)
USD
A
ARDX
1.815
(26.7897%)
USD
C
CASI
0.27
(11.1111%)
USD
C
CPHI
0.0164
(5.6049%)
USD
C
CTIC
0.11
(2.5404%)
USD
D
DARE
0.0027
(0.8646%)
USD
E
ENLV
-0.02
(-1.2195%)
USD
E
EPIX
0.03
(0.4317%)
USD
G
GLSI
0.14
(1.013%)
USD
K
KALA
-0.18
(-2.5605%)
USD
M
MTEM
-0.05
(-2.9412%)
USD
N
NDRA
-0.0005
(-0.1548%)
USD
R
RDHL
0.01
(2.2222%)
USD
S
STOK
0.34
(2.9085%)
USD
S
SNDL
0.06
(2.6432%)
USD
T
TNXP
0.0019
(1.0526%)
USD
T
TRVI
-0.02
(-0.6645%)
USD

Title:
Protalix BioTherapeutics

Sector:
Healthcare
Industry:
Biotechnology
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.
Do you need help or have a question?
Contact Us